Live video webcast on Tuesday, August 19th at 2:00 PM ET BOSTON and LONDON – August 14, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology …
Press Release
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better understand the multiple effects of its …
[Read more...] about Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of …
Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
– Video webcast now available on-demand BOSTON and LONDON – July 22, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its RecentlyGranted India Patent
Access the “What This Means” segment here BOSTON and LONDON – June 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
